ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Demographics"

  • Abstract Number: 1153 • ACR Convergence 2025

    New Disease Classification in the Block? A 5-year Retrospective Review on Clinical Profiles and Mortality Outcomes of Patients Presenting with Hematoinflammatory Syndromes at a University Center in Florida

    Cristine Kuzhuppilly Arcilla1, Gabriel Kirsch2, Michael Cargill2 and Gurjit Kaeley3, 1University of Florida Jacksonville, Jacksonville, FL, 2University of Florida - Jacksonville, Jacksonville, FL, 3UF COM-J, Ponte Vedra Beach, FL

    Background/Purpose: The novel diagnosis of VEXAS in 2020 led to the proposed possibility of a new category of hematoinflammatory syndromes linking clinically overlapping hematologic and…
  • Abstract Number: 2666 • ACR Convergence 2025

    Rare TNFAIP3 Hypomorphic Variants are a Massively Underestimated Driver of Human Autoinflammatory Disease

    Danica Lee1, Urekha Karri2, Yiming Luo3, Kader Cetin Gedik4, Manuel Carpio Tumba5, Prabal Chhibbar6, Priyamvada Roy6, Guido Falduto7, Jishnu Das5 and Daniella Schwartz5, 1University of Pittsburgh School of Medicine, Pittsburgh, PA, 2School of public health, Pittsburgh, PA, 3Columbia University, New York, NY, 4UPMC Children's Hospital of Pittsburgh/University of Pittsburgh, Pittsburgh, PA, 5University of Pittsburgh, Pittsburgh, PA, 6University of Pittsburgh School of Medicine, Pittsburgh, 7University of Pittsburgh Medical Center, Pittsburgh, PA

    Background/Purpose: TNFAIP3 encodes the ubiquitin editing enzyme A20, which inhibits multiple proinflammatory signaling pathways. Heterozygous germline mutations in TNFAIP3 cause the autoinflammatory disease Haploinsufficiency of…
  • Abstract Number: 1071 • ACR Convergence 2025

    Depression and Mental Health Service Gaps in Autoimmune Disease: Insights from a Simulated BRFSS Dataset

    Malay Rathod1, Shivani Modi2, Veera Durga Vaishnavi Kurra3, Karan Yagnik4 and Doantrnag Du4, 1Monmouth Medical Center, Ewing, NJ, 2Jefferson Einstein Montgomery Hospital, Ewign, NJ, 3University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Monmouth Medical Center, Long Branch, NJ

    Background/Purpose: Autoimmune diseases are complex conditions that may predispose individuals to an increased mental health burden, including depression. The immune system leads to inflammation in…
  • Abstract Number: 2615 • ACR Convergence 2025

    The Cost of Complexity: Financial Toxicity in Rheumatic Disease, Cancer, and Their Intersection

    Manush Sondhi1, Bhavik Bansal2, Hemant Khandelia1, Jiha Lee3, Sebastian E Sattui4, Siddharth Singh5 and Namrata Singh6, 1University of Washington, Seattle, WA, 2UT Southwestern Medical Center, Dallas, 3University of Michigan, Ann Arbor, MI, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 5University of California San Diego, San Diego, CA, 6University of Washington, Bellevue, WA

    Background/Purpose: Financial toxicity (FT) is the financial burden of accessing health care, well known in cancer and increasingly seen in rheumatic disease (RD). We compared…
  • Abstract Number: 1012 • ACR Convergence 2025

    Racial and Gender Disparities in Gout Clinical Trials

    Fizza Zulfiqar1, Dania Kaur2, Meaghan Bethea3, Taylor Spencer4, Samhitha Bitla5, Abhinav Vyas6 and Camelia Arsene7, 1Trinity Health Oakland/Wayne State University, Pontiac, MI, 2North Alabama Medical Center, Muscle Shoals, AL, 3Trinity Health Oakland Hopsital, Pontiac, MI, 4Trinity Health Oaklnd Hospital, Pontiac, MI, 5Trinity Health Oakland Hospital, Pontiac, MI, 6Vanderbilt University, Nashvile, TN, 7Trinity Health Oakland Hospital, Pontiac

    Background/Purpose: To develop effective novel treatment strategies for Gout disease that cater to patients from diverse backgrounds, it is crucial that all racial groups, without…
  • Abstract Number: 2558 • ACR Convergence 2025

    Impact of Social Determinants of Health on Patient Perceptions of Home Infusion Therapy in the Treatment of Rheumatologic Conditions

    Leslie Myers1, Elizabeth Neal2, Edward O'Bryan1, Michele Way3 and Timothy Walton1, 1CSI Pharmacy, Nash, 2CSI Pharmacy, Nash, TX, 3CSI Pharmacy, Olathe, KS

    Background/Purpose: Home infusion therapy is an established alternative site of care for patients requiring administration of infusion medications through a needle or catheter. Supported by…
  • Abstract Number: 0703 • ACR Convergence 2025

    Trends and Disparities in Systemic Sclerosis-related Mortality Rates in the United States from 1999 to 2023

    Nicolas Barnechea Alvarado1, Khadija Mohib1, Rameez Qasim2 and Muhammad Ali3, 1Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, 2Allama Iqbal Medical College Lahore, Lahore, Pakistan, 3Dow International Medical College, Karachi, Sindh, Pakistan

    Background/Purpose: Systemic sclerosis is one of the most fatal rheumatologic diseases, with significantly higher mortality rates compared to the general population, likely due to its…
  • Abstract Number: 2537 • ACR Convergence 2025

    Variation in Treatment Approaches in IgA-Vasculitis Among Pediatricians and Pediatric rheumatologists: A Cross-Sectional International Survey

    Merav Heshin Bekenstein1, Tali Elbaz2, Yael Illous2 and Barak Kandell3, 1Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, 2School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv, Israel, 3The Academic College of Tel Aviv-Yafo, Tel Aviv, Israel

    Background/Purpose: IgA Vasculitis (IgAV) is the most common small-vessel vasculitis in children. Although there is no evidence-based recommendations for treating IgAV, the European SHARE recommendations…
  • Abstract Number: 0580 • ACR Convergence 2025

    Persistence and Disease Activity Control among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy

    Philip J. Mease1, Nicole Middaugh2, Yolanda Muñoz Maldonado2, Chao Song3, Melissa Eliot2, Robert Low3 and Alexis Ogdie4, 1Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 2CorEvitas, LLC, Waltham, MA, 3UCB, Smyrna, GA, 4University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic disease that causes inflammation of the joints, entheses, spine, skin, and nails.1 While available advanced treatments (txs) for…
  • Abstract Number: 2099 • ACR Convergence 2025

    Incidence and Prevalence of Osteoarthritis in the United States Compared to Global Trends: Insights from the Global Burden of Disease Study (1990–2021)

    Khadija Mohib1, Rameez Qasim2, Nicolas Barnechea Alvarado1, ZAUHA FAWAD MEMON3 and Muhammad Asjad Saleem4, 1Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, 2Allama Iqbal Medical College Lahore, Lahore, Pakistan, 3Peoples University of Medical and Health Sciences for Women, Tando Allahyar, Sindh, Pakistan, 4Indus Hospital Karachi, Karachi

    Background/Purpose: Osteoarthritis (OA) is the most prevalent musculoskeletal condition, predominantly affecting individuals over the age of 55. According to the World Health Organization (WHO), OA…
  • Abstract Number: 0607 • ACR Convergence 2025

    Age at Diagnosis of SLE has Increased in a United States Longitudinal Cohort

    Daniel Goldman1, Andrea Fava2, Laurence Magder3 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Timonium, MD, 2Johns Hopkins University, Baltimore, MD, 3University of Maryland, Baltimore, Baltimore, MD

    Background/Purpose: The demographics of our lupus cohort have shifted over the decades towards an older population. While much of the shift can be attributed to…
  • Abstract Number: 2088 • ACR Convergence 2025

    Aging Unevenly: National Trends and Inequities in Osteoarthritis Mortality, 1999–2020

    Ghassan Makhoul1, Aziz-ur-Rahman Khalid2, Hasan Munshi1, Islam Rajab1, MD Walid Akram Hussain1, Reshma John1, Elvira Assaf1, Amer Al Badawy1, Barbare Khatiashvili1, Rouba Isshak1, Nargis Mateen3 and Robert Lahita4, 1St. Josephs University Medical Center, Paterson, 2St. Joseph's University Medical Center, wayne, 3St. Josephs University Medical Center, Paterson, NJ, 4St. Josephs University Medical Center, Wayne, NJ

    Background/Purpose: Osteoarthritis (OA) is a leading cause of disability and pain in older adults. While not traditionally viewed as fatal, OA contributes significantly to morbidity…
  • Abstract Number: 0579 • ACR Convergence 2025

    Characteristics and Treatment Patterns among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Disease-Modifying Antirheumatic Drug Therapy

    Philip J. Mease1, Nicole Middaugh2, Yolanda Muñoz Maldonado2, Chao Song3, Melissa Eliot2, Robert Low3 and Alexis Ogdie4, 1Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 2CorEvitas, LLC, Waltham, MA, 3UCB, Smyrna, GA, 4University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease affecting the joints, skin, and other regions of the body. It impacts up to 36%…
  • Abstract Number: 1996 • ACR Convergence 2025

    Hospital Burden of Crystal-related Arthritis in Spain: a nationwide dataset of 183,001 inpatients.

    Cristina RodrÍguez-Alvear1, Fernando Borrás2 and Mariano Andrés3, 1Virgen de la Peña General Hospital, Fuerteventura, Spain, 2Miguel Hernández University of Elche, Alicante, Spain, 3Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain

    Background/Purpose: Gout and calcium pyrophosphate crystal deposition disease (CPPD) are frequent in hospital settings. In Spain, last available data (2005-2015) indicated that 0.48% of hospital…
  • Abstract Number: 0744 • ACR Convergence 2025

    Age and Sex Influence on Clinical Manifestations of Giant Cell Arteritis: Results from the ARTESER Registry

    Delia Fernandez-Lozano1, Marta Domínguez-Álvaro2, Javier Narváez3, Noemí Garrido4, Eugenio de Miguel5, Paula Estrada-Alarcón6, Iñigo Hernández-Rodríguez7, Maite Silva-Diaz8, Joaquín M Belzunegui9, Clara Moriano10, Julio Sánchez Martín11, Itziar Calvo-Zorrilla12, Vicente Aldasoro Cáceres13, lydia Abasolo Alcazar14, Javier Loricera15, rafeal Benito-Melero16, Maria Garcia-Villanueva17, Fernando Sánchez-Alonso2, Santos Castañeda18, José L. Hernández19 and Ricardo Blanco20, 1Hospital Universitario y Politecnico La Fe, Valencia, Spain, 2Sociedad Española de Reumatología, Madrid, Spain, 3Hospital Universitario de Bellvitge, Barcelona, Spain, 4Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, 5Hospital Universitario La Paz, Madrid, Spain, 6Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, 7Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 8Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain, 9Hospital Universitario Donostia, San Sebastian, Spain, 10Hospital León, LEON, Castilla y Leon, Spain, 11Hospital Universitario 12 de Octubre, Madrid, Spain, 12Galdakao-Usansolo University Hospital, Bilbao, Spain, 13Hospital Universitario de Navarra, Pamplona, Spain, 14IdISSC. HCSC, Madrid, Madrid, Spain, 15Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 16MD, barcelona, Spain, 17Hospital Ramón y Cajal, Madrid, Spain, 18Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, 19Instituto de Investigación Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain, 20Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain

    Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis that predominantly affects older adults, with a higher prevalence in women. Previous studies exploring sex-related…
  • 1
  • 2
  • 3
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology